Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | MC4R | P32245 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7234096 | 1.00 | CYP2D6 (0.59) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL11478237 | 1.00 | CYP2D6 (0.59) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL7234103 | 1.00 | CYP2D6 (0.59) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL7239440 | 1.00 | CYP2D6 (0.59) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL2177322 | 0.88 | CYP2D6 (0.55) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL6097455 | 0.82 | CYP2D6 (0.65) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL48088 | 0.78 | CYP2D6 (0.61) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL2916607 | 0.78 | CYP2D6 (0.61) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL9596277 | 0.78 | CYP2D6 (0.61) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL2921816 | 0.78 | CYP2D6 (0.61) | CYP2D6MC4ROPRM1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6620945-B2 | Squalene synthetase inhibitors; antilipemic agents, anticholesterol agents | EISAI CO., LTD. (JP) | 2003-09-16 | — | — | US | disclosed |
| US-20030004208-A1 | Process for producing stereoisomer of pyrrolidine derivative | EISAI CO., LTD. (JP) | 2003-01-02 | — | — | US | disclosed |
| EP-1256573-A1 | Process for producing stereoisomer of pyrrolidine derivative | Eisai Co., Ltd. (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004208-A1 | Process for producing stereoisomer of pyrrolidine derivative | DHPS, SQLE, FDFT1 | CYP2D6 1174/4885MC4R 1179/4885OPRM1 2738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.